TAM
LFCR icon

Tocqueville Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Tocqueville Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Hold
151,700
– – 0.01% 395
2026
Q1 		$564K Hold
151,700
– – 0.01% 421
2025
Q4 		$1.24M Hold
151,700
– – 0.02% 357
2025
Q3 		$1.12M Hold
151,700
– – 0.02% 358
2025
Q2 		$1.23M Hold
151,700
– – 0.02% 338
2025
Q1 		$1.07M Hold
151,700
– – 0.02% 337
2024
Q4 		$1.13M Hold
151,700
– – 0.02% 347
2024
Q3 		$748K Hold
151,700
– – 0.01% 371
2024
Q2 		$778K Sell
151,700
-200,000
-57% -$1.18M 0.01% 359
2024
Q1 		$1.87M Sell
351,700
-50,000
-12% -$358K 0.03% 278
2023
Q4 		$2.49M Hold
401,700
– – 0.05% 237
2023
Q3 		$3.03M Sell
401,700
-50,000
-11% -$457K 0.06% 222
2023
Q2 		$4.37M Sell
451,700
-93,500
-17% -$571K 0.08% 192
2023
Q1 		$2.06M Sell
545,200
-13,300
-2% -$74.1K 0.04% 263
2022
Q4 		$3.62M Sell
558,500
-44,400
-7% -$366K 0.07% 219
2022
Q3 		$5.36M Sell
602,900
-5,550
-0.9% -$56.4K 0.11% 173
2022
Q2 		$6.07M Buy
608,450
+115,000
+23% +$1.14M 0.11% 180
2022
Q1 		$5.71M Buy
493,450
+71,500
+17% +$796K 0.09% 217
2021
Q4 		$4.68M Buy
421,950
+131,850
+45% +$1.28M 0.06% 262
2021
Q3 		$2.67M Buy
290,100
+40,000
+16% +$435K 0.04% 327
2021
Q2 		$2.81M Buy
250,100
+94,300
+61% +$1.09M 0.04% 334
2021
Q1 		$1.65M Buy
155,800
+32,900
+27% +$370K 0.03% 389
2020
Q4 		$1.33M Hold
122,900
– – 0.02% 399
2020
Q3 		$1.2M Buy
122,900
+1,300
+1% +$12.4K 0.02% 377
2020
Q2 		$968K Buy
121,600
+2,800
+2% +$28.9K 0.02% 394
2020
Q1 		$1.03M Buy
118,800
+5,350
+5% +$55.7K 0.03% 351
2019
Q4 		$1.28M Hold
113,450
– – 0.02% 415
2019
Q3 		$1.23M Hold
113,450
– – 0.02% 435
2019
Q2 		$1.06M Buy
+113,450
New +$1.15M 0.01% 474
2013
Q3 		– Sell
-18,474
Closed -$244K – 936
2013
Q2 		$244K Buy
+18,474
New +$255K ﹤0.01% 834

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Tocqueville Asset Management's LFCR Position: Q2 2026 in Review

Tocqueville Asset Management held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 151,700 shares worth $796K. The position accounts for 0.01% of the portfolio, ranked #395.

Tocqueville Asset Management first reported a position in LFCR in Q2 2013 and has held it in 30 quarters since. The position peaked at $6.07M in Q2 2022. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Tocqueville Asset Management held 151,700 shares of Lifecore Biomedical worth $796K as of Q2 2026.
  • Tocqueville Asset Management left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up 0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #395 holding.
  • Tocqueville Asset Management first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 30 quarters since.
  • Tocqueville Asset Management's Lifecore Biomedical position peaked at $6.07M in Q2 2022.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.